Intranasal sphenopalatine ganglion block for headache after a ruptured brain aneurysm
Official title: Intranasal Sphenopalatine Ganglion Blockade as a Non-invasive, Opioid-sparing Treatment for Headaches Following Aneurysmal Subarachnoid Hemorrhage
Run by Wright State University · NCT07116408 · Data updated 2026-11-12
This will test whether spraying a numbing medicine into the back of the nose can reduce severe headache in adults recovering from a ruptured brain aneurysm.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Wright State University Academic / other |
| Locations | 1 site (Dayton, Ohio) |
| Status | Recruiting |
| Started | May 20, 2024 |
| Main results expected | November 2026 |
| Study ends | May 2027 |
| Registry record updated | May 27, 2026 |
| Trial ID | NCT07116408 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) treated for aneurysmal subarachnoid hemorrhage in the neuro ICU who have Hunt and Hess scores of 0–3, can verbally report headache, and can consent are ideal candidates.
✕Probably not a fit
Patients with Hunt and Hess scores of 4–5, lidocaine allergy, pregnancy, certain nasal or bleeding contraindications, inability to consent, prisoners, or other excluded vulnerable groups are not eligible and unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional Phase 4 trial tests an intranasal sphenopalatine ganglion (SPG) block using lidocaine delivered via the Tx 360 device to treat headache after aneurysmal subarachnoid hemorrhage. All participants continue to receive standard pain medicines as needed while investigators record pain scores and side effects. The SPG block targets a nerve bundle linked to head pain and has shown benefit in other headache disorders and in a small pilot for SAH-related pain. The goal is to reduce headache intensity and opioid-related side effects without adding new adverse effects.
Why it matters
Potential benefit: If successful, this approach could lessen severe headache and reduce the need for opioid pain medicines, lowering sedation and breathing-related side effects.
How similar studies have gone: Small pilot data and successful use of SPG blockade in cluster and other headache disorders suggest promise, but large randomized evidence specifically for aSAH headaches is lacking.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: • Patients aged 18 years or older who are being treated in the neurologic ICU for subarachnoid hemorrhage with Hunt and Hess scale of 0-3 (Scale ranges from 0 to 5 with higher numbers indicating more severe symptoms) and able to verbally report headache will be considered for inclusion in this study. Exclusion Criteria: * Patients under the age of 18 years of age. * Patients with an allergy to lidocaine. * Patients from all vulnerable groups. * Patients with Hunt and Hess scale score of 4-5. (Scale ranges from 0 to 5 with higher numbers indicating more severe symptoms.) * Patients who are not able to consent. * Mentally impaired patients that are unable to provide consent. * Patients that are prisoners. * Pregnant patients. Additionally, patients with contraindications to use of the Tx 360 device will be excluded. Contraindications include: * History of recurrent nose bleeds. * Nasal septal deformity such as cleft lip and palate, choanal atresia (narrowed nasal passages), atrophic rhinitis, rhinitis medicamentosa, septal perforation, nasal/midface trauma. * Recent nasal/sinus surgery * Presence of a bleeding disorder (eg., Von Willebrand's disease or hemophilia). * Severe respiratory distress. * Presence of angiofibroma, sinus tumor, or granulomatous disease of the nasopharynx. * Presence of nasal trauma. * Nasal congestion that has been present more than 10 days, high fever, or abnormal appearance of the nasal mucosa or mucus.
Where it's running
-
Miami Valley Hospital
Dayton, Ohio, United States Recruiting
Study contacts
- Study coordinator: John B Terry, MD
- Email: jbterry@premierhealth.com
- Phone: 937-208-4200
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HEADS Registry: Headache, Ear, Auditory, Dizziness, and Sinus</n> Registry
This registry tests whether collecting online symptom reports from adults in the U.S. with sinus, vestibular, ear, or headache symptoms can help improve diagnosis and treatment.
-
Immediate neck manual therapy effects on atlas position and neck muscles
This trial tests two upper neck manual therapy techniques to see their immediate effect on neck alignment, atlas position, and a neck muscle shape in adults with head and neck pain or headaches.
-
Vitamin IV lidocaine before fundal pressure to prevent headache after cesarean using spinal anesthesia
This trial tests whether a single intravenous dose of lidocaine given before fundal pressure during cesarean delivery reduces the chance or severity of headache.
-
Muscle Position and Dry Needling Efficacy
This study tests whether the position of the upper trapezius during dry needling changes pain and function for people with chronic neck pain.
-
Gentle ear vagus nerve stimulation to reduce headache after aneurysm stent coiling
This study will try a noninvasive ear vagus nerve stimulation device to see if it reduces postoperative headaches in adults having stent-assisted coiling or flow-diverter treatment for unruptured brain aneurysms.
-
Surgical masks versus N95 masks for operating room nurses' symptoms from surgical smoke
This test compares whether surgical masks or N95 masks reduce physical symptoms from surgical smoke in operating room nurses.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.